Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alex Odermatt

Showing results (1-10 of 220) with videos related to

Pageof 22
Sort By:
Expert Opinion on Therapeutic Patents|September 29, 2009
Diazepane-acetamide derivatives as selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitorsAlex Odermatt
American Journal of Physiology. Renal Physiology|September 2, 2011
The Western-style diet: a major risk factor for impaired kidney function and chronic kidney diseaseAlex Odermatt
Swiss Medical Weekly|January 28, 2004
Corticosteroid-dependent hypertension: environmental influencesAlex Odermatt
The Journal of Steroid Biochemistry and Molecular Biology|August 26, 2014
11β-Hydroxysteroid dehydrogenase 1: Regeneration of active glucocorticoids is only part of the storyAlex Odermatt, Petra Klusonova
Molecular and Cellular Endocrinology|March 14, 2019
Subcellular localization and membrane topology of 17β-hydroxysteroid dehydrogenasesMaria Tsachaki, Alex Odermatt
Biochemical Pharmacology|September 4, 2008
Glucocorticoid and mineralocorticoid action: why should we consider influences by environmental chemicals?Alex Odermatt, Christel Gumy
Endocrine, Metabolic & Immune Disorders Drug Targets|June 23, 2007
Readjusting the glucocorticoid balance: an opportunity for modulators of 11beta-hydroxysteroid dehydrogenase type 1 activity?Atanas G Atanasov, Alex Odermatt
The Journal of Steroid Biochemistry and Molecular Biology|January 27, 2010
The glucocorticoid-activating enzyme 11beta-hydroxysteroid dehydrogenase type 1 has broad substrate specificity: Physiological and toxicological considerationsAlex Odermatt, Lyubomir G Nashev
Endocrinology|January 31, 2009
Retinoic acid reduces glucocorticoid sensitivity in C2C12 myotubes by decreasing 11beta-hydroxysteroid dehydrogenase type 1 and glucocorticoid receptor activitiesEvelyne M Aubry, Alex Odermatt
Molecular and Cellular Endocrinology|January 23, 2021
Antifungal therapy with azoles and the syndrome of acquired mineralocorticoid excessKatharina R Beck, Alex Odermatt
Pageof 22

Showing results (1-10 of 220) with videos related to

Sort By:
Pageof 22
Expert Opinion on Therapeutic Patents|September 29, 2009
Diazepane-acetamide derivatives as selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitorsAlex Odermatt
American Journal of Physiology. Renal Physiology|September 2, 2011
The Western-style diet: a major risk factor for impaired kidney function and chronic kidney diseaseAlex Odermatt
Swiss Medical Weekly|January 28, 2004
Corticosteroid-dependent hypertension: environmental influencesAlex Odermatt
The Journal of Steroid Biochemistry and Molecular Biology|August 26, 2014
11β-Hydroxysteroid dehydrogenase 1: Regeneration of active glucocorticoids is only part of the storyAlex Odermatt, Petra Klusonova
Molecular and Cellular Endocrinology|March 14, 2019
Subcellular localization and membrane topology of 17β-hydroxysteroid dehydrogenasesMaria Tsachaki, Alex Odermatt
Biochemical Pharmacology|September 4, 2008
Glucocorticoid and mineralocorticoid action: why should we consider influences by environmental chemicals?Alex Odermatt, Christel Gumy
Endocrine, Metabolic & Immune Disorders Drug Targets|June 23, 2007
Readjusting the glucocorticoid balance: an opportunity for modulators of 11beta-hydroxysteroid dehydrogenase type 1 activity?Atanas G Atanasov, Alex Odermatt
The Journal of Steroid Biochemistry and Molecular Biology|January 27, 2010
The glucocorticoid-activating enzyme 11beta-hydroxysteroid dehydrogenase type 1 has broad substrate specificity: Physiological and toxicological considerationsAlex Odermatt, Lyubomir G Nashev
Endocrinology|January 31, 2009
Retinoic acid reduces glucocorticoid sensitivity in C2C12 myotubes by decreasing 11beta-hydroxysteroid dehydrogenase type 1 and glucocorticoid receptor activitiesEvelyne M Aubry, Alex Odermatt
Molecular and Cellular Endocrinology|January 23, 2021
Antifungal therapy with azoles and the syndrome of acquired mineralocorticoid excessKatharina R Beck, Alex Odermatt
Pageof 22